Cited by 1,419SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index, and 1 are not checked yet.

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Open access

Seow, Jeffrey, Graham, Carl, Merrick, Blair, Acors, Sam, Pickering, Suzanne, Steel, Kathryn J. A., Hemmings, Oliver, O’Byrne, Aoife, Kouphou, Neophytos, Galao, Rui Pedro, Betancor, Gilberto, Wilson, Harry D., Signell, Adrian W., Winstone, Helena, Kerridge, Claire, Huettner, Isabella, Jimenez-Guardeño, Jose M., Lista, Maria Jose, Temperton, Nigel, Snell, Luke B., Bisnauthsing, Karen, Moore, Amelia, Green, Adrian, Martinez, Lauren, Stokes, Brielle, Honey, Johanna, Izquierdo-Barras, Alba, Arbane, Gill, Patel, Amita, Tan, Mark Kia Ik, O’Connell, Lorcan, O’Hara, Geraldine, MacMahon, Eithne, Douthwaite, Sam, Nebbia, Gaia, Batra, Rahul, Martinez-Nunez, Rocio, Shankar-Hari, Manu, Edgeworth, Jonathan D., Neil, Stuart J. D., Malim, Michael H., Doores, Katie J.·2020·Nature Microbiology

DOI 10.1038/s41564-020-00813-8PMC PMC7610833

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID 50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID 50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41564-020-00813-8

Cites

75 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · cited 1×
“4) for at least 12 h; (3) Requirement for non-invasive ventilation/continuous positive airway pressure or proning or supplemental oxygen (FiO2 > 0.”
Background
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
Whittaker, E., Bamford, A., Kenny, J. M., Kaforou, M., Jones, C. E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020) · JAMA · doi:10.1001/jama.2020.10369 · Cited by 1,996
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · cited 1×
“8) and peripheral oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h; (5) Requirement for ECMO.”
Background
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434

Show all 62 references

Sorted by citations

Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships
Popkin, B. M., Du, S., Green, W. D., Beck, M. A., Algaith, T., Herbst, C. H., Alsukait, R. F., Alluhidan, M., Alazemi, N., & Shekar, M. (2020) · Obesity Reviews · doi:10.1111/obr.13128 · Cited by 1,150
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Self-citation
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Virology, transmission, and pathogenesis of SARS-CoV-2
Çevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. J. S. (2020) · BMJ · doi:10.1136/bmj.m3862 · Cited by 781
Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers”
Graham, E. L., Clark, J. R., Orban, Z. S., Lim, P. H., Szymanski, A. L., Taylor, C., DiBiase, R. M., Jia, D. T., Balabanov, R., Ho, S. U., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51350 · Cited by 693
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30773-8 · Cited by 633
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Monin, L., Laing, A. G., Muñoz‐Ruiz, M., McKenzie, D. R., del Barrio, I. D. M., Alaguthurai, T., Domingo‐Vila, C., Hayday, T. S., Graham, C., Seow, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00213-8 · Cited by 611
“22 We used a recently described neutralisation assay 17–19 and found that all responders, with the exception of a single responder with haematological cancer, could neutralise the wild-type strain (figure 1C).”
InfluentialSelf-citation
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Rénia, L., & Remuzzi, G. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 616
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32137-1 · Cited by 572
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Ebinger, J. E., Fert‐Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J. C., Frias, E. C., Stewart, J. L., Eyk, J. E. V., Braun, J. G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01325-6 · Cited by 532
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 532
“8) Duration of symptoms in days (median [range]) 14 (1-43) 13 (6-30)”
Background
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Abani, O., Abbas, A. H., Abbas, F., Abbas, M. A., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00897-7 · Cited by 493
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1555 · Cited by 475
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 483
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection
Carter, M. J., Fish, M., Jennings, A., Doores, K. J., Wellman, P., Seow, J., Acors, S., Graham, C., Timms, E., Kenny, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1054-6 · Cited by 419
Self-citation
SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals
Gassen, N. C., Papies, J., Bajaj, T., Emanuel, J., Dethloff, F., Chua, R. L., Trimpert, J., Heinemann, N., Niemeyer, C., Weege, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24007-w · Cited by 413
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
Braga, L., Ali, H., Secco, I., Chiavacci, E., Neves, G., Goldhill, D. H., Penn, R., Jiménez-Guardeño, J. M., Ortega‐Prieto, A. M., Bussani, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03491-6 · Cited by 402
Self-citation
Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection
Tali, S. H. S., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi‐Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 430
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Antibody response to SARS-CoV-2 infection in humans: A systematic review
Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244126 · Cited by 379
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351
Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19
Bacher, P., Rosati, E., Esser, D., Martini, G. R., Saggau, C., Schiminsky, E., Dargvainiene, J., Schröder, I., Wieters, I., Khodamoradi, Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.016 · Cited by 314
T cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245532 · Cited by 352
COVID‐19 and Toll‐Like Receptor 4 (TLR4): SARS‐CoV‐2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation
Aboudounya, M. M., & Heads, R. J. (2021) · Mediators of Inflammation · doi:10.1155/2021/8874339 · Cited by 359
“However, since neutralising antibodies against SARS-CoV-2 have been shown to decline over a period of only 3 months postinfection in humans [13], there is a need to adopt a parallel treat-ment strategy that involves the innate immune system, besides antiviral drugs.”
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
Dispinseri, S., Secchi, M., Pirillo, M. F., Tolazzi, M., Borghi, M., Brigatti, C., Angelis, M. L. D., Baratella, M., Bazzigaluppi, E., Venturi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22958-8 · Cited by 338
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C. M., Weinkauf, C. C., Bime, C., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.004 · Cited by 338
Neutralizing antibody titres in SARS-CoV-2 infections
Lau, E. H. Y., Tsang, O. T., Hui, D. S. C., Kwan, M. Y. W., Chan, W. H., Chiu, S. S. S., Ko, R. L., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20247-4 · Cited by 331
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Peluso, M. J., Lu, S., Tang, A. F., Durstenfeld, M. S., Ho, H.-E., Goldberg, S. A., Forman, C. A., Munter, S. E., Hoh, R., Tai, V., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab490 · Cited by 332
Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein
Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M. V., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.006 · Cited by 318
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004107 · Cited by 307
“There are several possible explanations for lower seroprevalence in children: milder infections, which are generally associated with lower antibody titers [50]; school closures; and ineligibility for vaccination.”
Background
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaill, J., Pillet, S., Grattard, F., Gonzalo, S., Verhoeven, P. O., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00588-2 · Cited by 308
Impact of COVID-19 pandemic on socio-economic, energy-environment and transport sector globally and sustainable development goal (SDG)
Nundy, S., Ghosh, A., Mesloub, A., Albaqawy, G. A., & Alnaim, M. M. (2021) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2021.127705 · Cited by 319
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K. T., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 314
Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients
Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa659 · Cited by 308
Not just antibodies: B cells and T cells mediate immunity to COVID-19
Cox, R. J., & Brokstad, K. A. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00436-4 · Cited by 295
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers
Lumley, S., Wei, J., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab004 · Cited by 281
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L. M., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20654-7 · Cited by 287
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Bettini, E., & Locci, M. (2021) · Vaccines · doi:10.3390/vaccines9020147 · Cited by 292
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
Prendecki, M., Clarke, C., Brown, J., Cox, A., Gleeson, S., Guckian, M., Randell, P., Pria, A. D., Lightstone, L., Xu, X.-N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00502-x · Cited by 271
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D. J., Wang, Z., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey‐Tubman, K. E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.008 · Cited by 279
“Nevertheless, variability and decay of convalescent neutralizing titers (Gaebler et al., 2021; Luchsinger et al., 2020; Muecksch et al., 2021; Robbiani et al., 2020; Seow et al., 2020) suggests that reinfection by SARS-CoV-2 may occur with some frequency.”
Background
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273
“…of the virus in serum, and to a lesser degree also at mucosal surfaces, have been well characterized with respect to their kinetics, binding capacity, and functionality (Grandjean et al., 2020; Isho et al., 2020; Iyer et al., 2020; Ripperger et al., 2020; Seow et al., 2020; Wajnberg et al., 2020).”
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Tebas, P., Yang, S., Boyer, J., Reuschel, E. L., Patel, A. R., Christensen-Quick, A., Andrade, V. M., Morrow, M. P., Kraynyak, K. A., Agnes, J. T., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100689 · Cited by 268
Self-citation
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., & Patalon, T. (2021) · Nature Communications · doi:10.1038/s41467-021-26672-3 · Cited by 261
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
Bégin, P., Callum, J., Jamula, E., Cook, R. J., Heddle, N. M., Tinmouth, A. T., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01488-2 · Cited by 258
Self-citation
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
Peluso, M. J., Deitchman, A. N., Torres, L., Iyer, N. S., Munter, S. E., Nixon, C. C., Donatelli, J. L., Thanh, C., Takahashi, S., Hakim, J. M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109518 · Cited by 251
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Galipeau, Y., Greig, M., Liu, C., Driedger, M., & Langlois, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 247
“However, while IgM peaks at approximately 10 to 12 days, IgA levels appear to be relatively more persistent, peaking at approximately 20 to 30 Frontiers in Immunology | www.frontiersin.org 8 days PSO (39, 123, 124, 133).”
Influential
SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 + T cell activation in COVID-19 patients
Saini, S. K., Hersby, D. S., Tamhane, T., Povlsen, H. R., Hernandez, S. P. A., Nielsen, M., Gang, A. O., & Hadrup, S. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf7550 · Cited by 226
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
Wu, J., Liang, B., Chen, C., Wang, H., Fang, Y., Shěn, S., Yang, X., Wang, B., Chen, L., Chen, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22034-1 · Cited by 255
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Halperin, S. A., Ye, L., MacKinnon‐Cameron, D., Smith, B. R., Cahn, P. E., Ruiz-Palacios, G. M., Ikram, A., Lanas, F. T., Guerrero, M. L., Navarro, S. R. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02753-7 · Cited by 222
Vaccines for COVID-19
Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13517 · Cited by 226
COVID-19 Antibody Tests and Their Limitations
Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 226
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
Writing Committee for the REMAP-CAP Investigators, Abdelhady, H., Abdelrazik, M., Abdi, Z., Abdo, D., Abdulle, A., Abel, L., Abouzeenni, S., Abrahamson, G., Abusamra, Y., et al. (2021) · JAMA · doi:10.1001/jama.2021.18178 · Cited by 212
Self-citation
Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial
Gutiérrez‐Castrellón, P., Gandara-Martí, T., y Abreu, A. T. A., Nieto-Rufino, C. D., López-Orduña, E., Jiménez–Escobar, I., Jiménez-Gutiérrez, C., López‐Velázquez, G., & Espadaler, J. (2022) · Gut Microbes · doi:10.1080/19490976.2021.2018899 · Cited by 220
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 225
The effect of spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108890 · Cited by 221
“Cells were transfected using 60 mg of PEI-Max (Polysciences) with amix of three plasmids: 9.1 mgHIV-1 luciferase reporter vector (Seow et al., 2020), 9.1 mg HIV p8.”
InfluentialSelf-citation
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study
He, Z., Ren, L., Yang, J., Guo, L., Feng, S., Ma, C., Wang, X., Leng, Z., Tong, X., Zhou, W., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00238-5 · Cited by 226
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses
Bonifacius, A., Tischer‐Zimmermann, S., Dragon, A. C., Gussarow, D., Vogel, A., Krettek, U., Gödecke, N., Yılmaz, M., Kraft, A. R. M., Hoeper, M. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.008 · Cited by 208
“Recent reports that COVID-19 patients become seronegative early during convalescence (Long et al., 2020; Seow et al., 2020; Ward et al., 2020) raise the question of whether recovery from COVID-19 confers immunity to reinfection, as was shown in a rhesus macaque model (Chandrashekar et al.”
Background
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
Reynolds, C. J., Swadling, L., Gibbons, J. M., Pade, C., Jensen, M. P., Diniz, M. O., Schmidt, N. M., Butler, D. K., Amin, O. E., Bailey, S. N. L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf3698 · Cited by 196
Self-citation
A simple protein-based surrogate neutralization assay for SARS-CoV-2
Abe, K. T., Li, Z., Samson, R., Samavarchi‐Tehrani, P., Valcourt, E. J., Wood, H., Budylowski, P., Dupuis, A. P., Girardin, R. C., Rathod, B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142362 · Cited by 200
Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases
Carsetti, R., Zaffina, S., Mortari, E. P., Terreri, S., Corrente, F., Capponi, C., Palomba, P., Mirabella, M., Cascioli, S., Palange, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610300 · Cited by 201
Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults
Ward, H., Cooke, G., Atchison, C. J., Whitaker, M. D., Elliott, J., Moshe, M., Brown, J. C., Flower, B., Daunt, A., Ainslie, K. E. C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100098 · Cited by 198
Viral persistence, reactivation, and mechanisms of long COVID
Chen, B. K., Jülg, B. D., Mohandas, S., Bradfute, S. B., & RECOVER Mechanistic Pathways Task Force (2023) · eLife · doi:10.7554/elife.86015 · Cited by 211
The humoral response and antibodies against SARS-CoV-2 infection
Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 195
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
Beaudoin-Bussières, G., Laumaea, A., Anand, S. P., Prévost, J., Gasser, R., Goyette, G., Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020) · mBio · doi:10.1128/mbio.02590-20 · Cited by 189
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend, J. P., Hassler, H. B., Wang, Z., Miura, S., Singh, J., Kumar, S., Ruddle, N. H., Galvani, A. P., & Dornburg, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00219-6 · Cited by 186
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
Chen, Y., Zuiani, A., Fischinger, S., Mullur, J., Atyeo, C. G., Travers, M. E., Lelis, F., Pullen, K. M., Martin, H., Tong, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.051 · Cited by 182
Inefficiency of SIR models in forecasting COVID-19 epidemic: a case study of Isfahan
Moein, S., Nickaeen, N., Roointan, A., Borhani, N., Heidary, Z., Javanmard, S. H., Ghaisari, J., & Gheisari, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-84055-6 · Cited by 184
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
Abu-Raddad, L. J., Chemaitelly, H. S., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Al‐Khal, A., Al‐Kuwari, E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1846 · Cited by 176
“The intensity of the epidemic with a high risk of re-exposure to the infection, as well as the availability of a centralized data-capture system of all laboratory-confirmed infections, provided an opportunity to epidemiologically assess the presence and incidence of reinfections; a poorly-understood feature of SARS-Co…”
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.015 · Cited by 153
“S-specific IgM, IgA, and IgG antibodies are detected early after infection (Long et al., 2020; Seow et al., 2020) and IgG antibody levels and IgG memory B cells can persist post-infection (Dan et al.”
SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
Lewis, H., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · doi:10.1101/2022.02.14.22270934 · Cited by 177
SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
Lewis, H. C., Ware, H., Whelan, M. G., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noël, K. C., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008793 · Cited by 172
“58 SARS- CoV-2 seroprevalence is high and heterogenous in Africa, suggesting greater population exposure to SARS- CoV-2 and potential protection against COVID-19 severe disease than has been previously indicated by confirmed case data and vaccine coverage.”
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
Anand, S. P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S. Y., Bourassa, C., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100290 · Cited by 174
“Longitudinal data from a larger sample size with varying clinical symptoms ranging from asymptomatic to critical cases as well as individuals below 20 years and over 65 years of age would be required for a more precise understanding of the overall immune durability against COVID-19.”
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
Stadlbauer, D., Tan, J., Jiang, K., Hernandez, M. M., Fabre, S., Amanat, F., Teo, C., Arunkumar, G. A., McMahon, M., Capuano, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2912-6 · Cited by 168
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword
Tan, L. Y., Komarasamy, T. V., & Balasubramaniam, V. R. M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742941 · Cited by 184
“seropositivity Significant decline in neutralising antibodies titres & seropositivity (63, 66)”
Background
SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
Sano, K., Bhavsar, D., Singh, G., Floda, D. L., Srivastava, K., Gleason, C., PARIS Study Group, Amoako, A. A., Andre, D., Beach, K. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32389-8 · Cited by 167
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Ortega, N., Ribes, M., Vidal, M., Rubio, R., Aguilar, R., Williams, S. V., Barrios, D., Alonso, S., Hernández-Luis, P., Mitchell, R. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24979-9 · Cited by 174
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 169
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
CD8 + T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19
Mallajosyula, V. V. A., Ganjavi, C., Chakraborty, S., McSween, A. M., Pavlovitch-Bedzyk, A. J., Wilhelmy, J., Nau, A. N., Manohar, M., Nadeau, K. C., & Davis, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg5669 · Cited by 168
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
Gutmann, C., Takov, K., Burnap, S. A., Singh, B., Ali, H., Theofilatos, K., Reed, E., Hasman, M., Nabeebaccus, A., Fish, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23494-1 · Cited by 160
Self-citation
Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study
García‐Abellán, J., Padilla, S., Fernández‐González, M., García, J. A., Agulló, V., Galera, M. A., Ruiz, S., Galiana, A., Gutiérrez, F., & Masiá, M. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01083-7 · Cited by 157
“Severity of disease has actually been associated with the magnitude and duration of the antibody response [13].”
Background
SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort StudyPreprint
Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 153
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 151
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
Rosa, A., Pye, V. E., Graham, C., Muir, L., Seow, J., Ng, K. W., Cook, N., Rees-Spear, C., Parker, E. L., dos Santos, M. S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7607 · Cited by 142
Self-citation
Laboratory diagnosis of COVID-19
Goudouris, E. (2020) · Jornal de Pediatria · doi:10.1016/j.jped.2020.08.001 · Cited by 165
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 155
“Themajority of SARS-CoV-2 infected individuals have been shown to generate an antibody response 5– 15 days post onset of symptoms (POS) that peaks after 3– 4 weeks and then starts to decline (Crawford et al., 2020; Muecksch et al., 2020; Prévost et al., 2020; Seow et al., 2020).”
InfluentialSelf-citation
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198141 · Cited by 148

Authors: Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., Betancor, G., Wilson, H. D., Signell, A. W., Winstone, H., Kerridge, C., Huettner, I., Jimenez-Guardeño, J. M., Lista, M. J., Temperton, N., Snell, L. B., Bisnauthsing, K., Moore, A., Green, A., Martinez, L., Stokes, B., Honey, J., Izquierdo-Barras, A., Arbane, G., Patel, A., Tan, M. K. I., O’Connell, L., O’Hara, G., MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Shankar-Hari, M., Edgeworth, J. D., Neil, S. J. D., Malim, M. H., & Doores, K. J.
Affiliations: King's College London (GB)
Guy's Hospital (GB)
Medway School of Pharmacy (GB)
Guy's and St Thomas' NHS Foundation Trust (GB)
Corresponding author: Doores, Katie J.
ORCID: Seow, Jeffrey
Merrick, Blair
Acors, Sam
Pickering, Suzanne
Steel, Kathryn J. A.
Hemmings, Oliver
O’Byrne, Aoife
Kouphou, Neophytos
Galao, Rui Pedro
Betancor, Gilberto
Wilson, Harry D.
Signell, Adrian W.
Winstone, Helena
Jimenez-Guardeño, Jose M.
Temperton, Nigel
Snell, Luke B.
Bisnauthsing, Karen
Martinez, Lauren
Stokes, Brielle
Izquierdo-Barras, Alba
Patel, Amita
Tan, Mark Kia Ik
O’Connell, Lorcan
O’Hara, Geraldine
Douthwaite, Sam
Nebbia, Gaia
Batra, Rahul
Shankar-Hari, Manu
Edgeworth, Jonathan D.
Neil, Stuart J. D.
Malim, Michael H.
Doores, Katie J.
Venue: Nature Microbiology
Publisher: Springer Science and Business Media LLC
Published: 2020-10-26
Volume: 5
Issue: 12
Pages: 1598-1607
ISSN: 2058-5276 (ISSN-L)
DOI: 10.1038/s41564-020-00813-8
PMC: PMC7610833
OpenAlex: W3093667122
Cited by: 1,419
References: 62
Citations by year: 2026: 18 · 2025: 44 · 2024: 75 · 2023: 147 · 2022: 311 · 2021: 615 · 2020: 207
FWCI: 41.93
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Microbiology (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Kent Academic Repository (University of Kent) (acceptedVersion)
PubMed Central (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Research Portal (King's College London) (submittedVersion, other-oa)
Repositorio Institucional de la Universidad de Málaga (University of Málaga) (submittedVersion, cc-by-nc-nd)
Funders: RCUK | Medical Research Council (MC/PC/15068, MR/N013700/1, MR/R015643/1, MC/PC/15068, MR/R015643/1, MR/S023747/1)
Huo Family Foundation
Wellcome Trust (WT098049AIA, MR/S023747/1, 106223/Z/14/Z)
Huo Family Foundation King’s Together Rapid COVID-19 Call award
DH | National Institute for Health Research (CS-2016-16-011)
King’s Together Rapid COVID-19 Call award Huo Family Foundation
Fondation Dormeur, Vaduz King’s Together Rapid COVID-19 Call award Huo Family Foundation
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody waning, seroconversion, antibody kinetics, disease severity, infectious dose, reinfection protection, healthcare workers, booster vaccination, serological testing
MeSH terms: Seroconversion, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, Humans, Kinetics, Longitudinal Studies, Male, Middle Aged, Severity of Illness Index, Young Adult, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks